(HealthDay)—The addition of subcutaneous tirzepatide versus placebo to titrated insulin glargine results in significant improvements in glycemic control among patients with type 2 diabetes and inadequate glycemic control, ...
Feb 10, 2022
0
2
There are few treatment options for children with multiple sclerosis—a condition in which the immune system attacks the protective covering of nerves in the brain and spinal cord—and most therapies for the disease have ...
Nov 30, 2021
0
10
Levels of dopamine and the placebo effect can determine whether patients with social anxieties improve when treated with SSRIs. A new study shows the effect was four times higher for patients with high expectations of the ...
Nov 8, 2021
0
158
(HealthDay)—At five years, symptom severity does not differ, but rates of subsequent surgical treatment are lower in patients with idiopathic carpal tunnel syndrome receiving local methylprednisolone injection versus saline ...
Oct 29, 2021
0
2
Have you heard of a fractional carbon dioxide (CO2) laser?
Oct 12, 2021
0
58
(HealthDay)—For hospitalized adults with COVID-19, treatment with baricitinib in addition to standard of care does not reduce the frequency of disease progression overall, but it is associated with reduced mortality, according ...
Sep 8, 2021
0
12
Until now, patients with heart failure with preserved ejection fraction—the most common type of heart failure in the elderly—have had no access to evidenced-based treatments. For the first time, a large clinical trial ...
Aug 27, 2021
0
16
A pill has been shown to help keep certain early-stage, hard-to-treat breast cancers at bay after initial treatment in findings being reported early because they are so promising.
Jun 4, 2021
0
11
In a paper published today in Science Advances, researchers from the University of Pittsburgh School of Medicine showed that inhalable nanobodies targeting the spike protein of the SARS-CoV-2 coronavirus can prevent and treat ...
May 26, 2021
0
16
People who were exposed to COVID and received under-the-skin injections of Regeneron's synthetic antibody treatment were 81 percent less likely to develop the disease compared to those on a placebo, the company said Monday.
Apr 12, 2021
0
7
